Invitae (OTCPK:NVTA.Q) - Hisse Senedi Fiyatı, Haberler ve Analizler

NVTA.Q Stoklara Genel Bakış

A medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally.

Şirket hakkında

NVTA.Q temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	0/6
Temettüler	0/6

Ödüller

Risk Analizi

Negatif hissedar öz sermayesi

Kazançlar son 5 yılda yılda 53.3% oranında azaldı

Anlamlı bir piyasa değeri yok ( $115K )

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

+ 2 daha fazla risk

Invitae Corporation Rakipler

First Choice Healthcare Solutions

OTCPK:FCHS

US$112.1k

ETAO International

OTCPK:ETAO.F

US$1.5k

Medivolve

OTCPK:MEDV.F

US$164.8k

Cannabis Sativa

OTCPK:CBDS

US$1.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Invitae
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.0004
52 Haftanın En Yüksek Seviyesi	US$1.25
52 Haftanın En Düşük Seviyesi	US$0.000001
Beta	2.8
11 Aylık Değişim	-42.86%
3 Aylık Değişim	-76.47%
1 Yıllık Değişim	-99.97%
33 Yıllık Değişim	-100.00%
5 Yıllık Değişim	-100.00%
Halka arzdan bu yana değişim	-100.00%

Son Haberler & Güncellemeler

Recent updates

Cautious Investors Not Rewarding Invitae Corporation's (NYSE:NVTA) Performance Completely

Dec 20

Invitae maintains 2022 financial guidance as Q2 results beat on top and bottom lines

Aug 09

Hissedar Getirileri

	NVTA.Q	US Healthcare	US Pazar
7D	0%	4.2%	2.3%
1Y	-100.0%	6.9%	35.1%

Getiri vs. Endüstri: NVTA.Q geçen yıl % 6.9 oranında getiri sağlayan US Healthcare sektörünün gerisinde kaldı.

Getiri vs Piyasa: NVTA.Q geçen yıl % 35.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is NVTA.Q's price volatile compared to industry and market?
NVTA.Q volatility
NVTA.Q Average Weekly Movement	642.7%
Healthcare Industry Average Movement	6.9%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: NVTA.Q hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: NVTA.Q 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 571% dan 643% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2010	1,700	Ken Knight	www.invitae.com

Invitae Corporation Temel Bilgiler Özeti

Invitae'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
NVTA.Q temel i̇stati̇sti̇kler
Piyasa değeri	US$114.60k
Kazançlar(TTM)	-US$1.44b
Gelir(TTM)	US$481.58m

0.0x

P/S Oranı

0.0x

F/K Oranı

NVTA.Q aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
NVTA.Q gelir tablosu (TTM)
Gelir	US$481.58m
Gelir Maliyeti	US$350.95m
Brüt Kâr	US$130.64m
Diğer Giderler	US$1.57b
Kazançlar	-US$1.44b

Son Raporlanan Kazançlar

Sep 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-5.03
Brüt Marj	27.13%
Net Kâr Marjı	-299.14%
Borç/Özkaynak Oranı	-124.7%

NVTA.Q uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

NVTA.Q Stoklara Genel Bakış

Ödüller

Risk Analizi

Invitae Corporation Rakipler

OTCPK:FCHS

US$112.1k

OTCPK:ETAO.F

US$1.5k

OTCPK:MEDV.F

US$164.8k

OTCPK:CBDS

US$1.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Invitae Launches Unlock Behind the Seizure Program for Pediatric Epilepsy Patients

First Amended Disclosure Statement Approved for Invitae Corporation

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million.

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance

Invitae Launches Update to Invitae Generation: Clinical Variant Modeling Improves Variant Classification

Invitae Corporation Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023

Recent updates

Invitae Launches Unlock Behind the Seizure Program for Pediatric Epilepsy Patients

First Amended Disclosure Statement Approved for Invitae Corporation

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million.

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance

Invitae Launches Update to Invitae Generation: Clinical Variant Modeling Improves Variant Classification

Invitae Corporation Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023

Motion for Asset Sale Filed by Invitae Corporation

Invitae Corporation Filed for Bankruptcy

Invitae Corporation(OTCPK:NVTA) dropped from S&P TMI Index

The New York Stock Exchange to Commence Delisting Proceedings against Invitae

Invitae Corporation May File for Bankruptcy

New minor risk - Market cap size

Cautious Investors Not Rewarding Invitae Corporation's (NYSE:NVTA) Performance Completely

Invitae Corporation Announces Board Changes

Invitae Corporation Announces the Retirement of Robert L. Nussbaum as Chief Medical Officer, Effective December 29, 2023

Price target decreased by 11% to US$1.31

Invitae Corporation Appoints Ana J. Schrank as Chief Accounting Officer

Consensus EPS estimates fall by 119%

New major risk - Financial position

Invitae Corporation Reaffirms Earnings Guidance for the Full Year 2023

Price target increased by 30% to US$1.92

Third quarter 2023 earnings: EPS misses analyst expectations

Invitae Corporation to Report Q3, 2023 Results on Nov 08, 2023

Invitae Corporation Announces Findings from the Study to Date on Uncertain Results from Hereditary Disease Genetic Testing

Invitae Corporation Appoints David Sholehvar as Chief Operating Officer, Effective November 13, 2023

Price target decreased by 14% to US$1.58

Invitae Announces Results of Its Collaborative Study on Universal Hereditary Cancer Genetic Testing in All Patients with Breast Cancer in A Rural Population in the Annals of Surgical Oncology

Invitae Corporation Announces Change of Chief Financial Officer, Effective October 2, 2023

Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard

Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard

New major risk - Financial position

Invitae Corporation Announces Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer

Price target decreased by 13% to US$1.70

Consensus EPS estimates fall by 34%

Invitae Corporation Provides Revenue Guidance for the Year 2023

Invitae Corporation Provides Revenue Guidance for the Year 2023

Price target decreased by 8.2% to US$1.87

Second quarter 2023 earnings: EPS misses analyst expectations

Invitae: Revenue Troubles Build

Invitae Corporation to Report Q2, 2023 Results on Aug 08, 2023

Invitae Is Treading In Competitive Waters

Invitae Corporation Announces Executive Changes

Invitae Corporation's (NYSE:NVTA) Prospects Need A Boost To Lift Shares

Invitae Corporation Announces Nine Studies to Be Presented At the 2023 American Society of Clinical Oncology Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology

Invitae Announces CFO Changes

President recently sold US$54k worth of stock

Invitae Corporation Announces It Intends to Appeal the Verdict Delivered by A Jury At the United States District Court

Consensus EPS estimates fall by 19%

First quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 10.0% to US$2.26

Full year 2022 earnings: EPS misses analyst expectations

Invitae Corporation to Report Q4, 2022 Results on Feb 28, 2023

Price target decreased by 7.4% to US$2.51

Invitae Corporation Appoints William H. Osborne to its Board of Directors

Invitae: What Happened At The JP Morgan Health Conference

Invitae guides Q4 revenue above estimates

Director recently sold US$115k worth of stock

Invitae Likely Hasn't Reached The Bottom Yet

Invitae Releases Data Use Transparency Report, Demonstrating the Impact of Patient Data on Genetic Research